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Abstract
The US Institute of Medicine’s focus on patient safety has
motivated hospital administrators to facilitate a culture of safety. As
a result, subcommittees of the pharmacy and therapeutics
committee have emerged in many hospitals to focus on adverse
events and patient safety. Antimicrobial harms have gained the
attention of practicing clinicians and hospital formulary committees,
because they top the list of drugs that are associated with adverse
events and because of certain serious harms that have ultimately
led to the withdrawal of some antimicrobial agents. In the near
future, several antimicrobials in the late phase of development will
become available for clinical use (ceftobiprole, ceftaroline, and
telavancin), and others (doripenem and dalbavancin) have recently
joined the armamentarium. Because new antimicrobials will
become part of the treatment armamentarium, it is important to
discuss our current understanding of antimicrobial harms in
general. Although not thought of as traditional adverse events,
Clostridium difficile infection and development of resistance during
therapy are adverse events that occur as a result of antimicrobial
exposure and therefore are discussed. In addition, a distillation of
our current understanding of β-lactam specific adverse events will
be provided. Finally, new methods of administration are being
evaluated that may influence peak concentration-related anti-
microbial adverse events.
Introduction
The safety of antibiotics has attracted attention lately in both
the scientific and regulatory communities. For example, in
2001, the Interscience Conference on Antimicrobial Agents
and Chemotherapy held a symposium entitled ‘Antibiotics to
die for’. In addition, the US Food and Drug Administration
(FDA) recently mandated a second change in the labeling of
telithromycin in less than a year because of safety concerns,
and has updated the language of antimicrobials regarding the
risk for Clostridium difficile infection [1]. Antibiotic safety is
an important component of both patient care and formulary
decision making. β-Lactams are typically considered to be
among the safest classes of antibiotics available to clinicians
practicing today. Although these agents are generally safe,
certain class effects exist that include serious hypersensitivity-
related harms, bone marrow suppression, and seizures. These
and other antimicrobial harms are discussed here.
General classification of adverse events
Type A events are predictable events that represent either an
excess of the drug’s primary pharmacologic effect (for
example, hypotension with a vasodilator) or a secondary
pharmacologic property (for example, anticholinergic effects
with tricyclic antidepressants) [2]. These events are typically
dose related, usually identified before marketing, and
generally listed in the product’s labeling. Although common
and capable of producing significant morbidity, they are rarely
fatal. In contrast, type B events are not an extension of the
known pharmacologic properties of a drug. These events,
which include idiosyncratic, immunologic/allergic, and
carcinogenic/teratogenic events, are generally unpredictable,
unrelated to dosing or route of administration, and are more
or less a function of the patient’s susceptibility to the effect
rather than intrinsic drug toxicity. Type B events can present
late, long after drug therapy has been discontinued, and
consequently they may not be recognized or attributed to the
drug because of the temporal disassociation. Although they
are the least common, type B events are among the most
serious and potentially life-threatening of the adverse events
[2].
Adverse immunologic events can also be classified on the
basis of their pathophysiology into types 1 through 4 and
idiopathic events [3,4]. Type 1 events are immunoglobulin
IgE-mediated, immediate hypersensitivity reactions that
produce urticaria, hives, or anaphylaxis. Events of types 2 and
3 are IgG-mediated or IgM-mediated delayed reactions. Type
2 events present as anemia, cytopenia, or interstitial nephritis,
whereas type 3 events present as serum sickness or drug
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fever. Type 4 events are T-cell-mediated, delayed reactions
that present as contact dermatitis. All other events are deemed
idiopathic. These idiopathic events can present as eosinophilia,
a maculopapular rash, or Stevens-Johnson syndrome.
The type and severity of adverse events associated with a
particular drug are influenced by a multitude of pharmaco-
logic and clinical factors. These include the drug’s pharmaco-
kinetic properties (absorption, distribution, metabolism, and
elimination); the dose, route, and duration of therapy; the
patient’s age and genetic composition; the presence of
concomitant disorders; and concurrent drug administration.
Sources of information for
antibiotic-associated adverse events
Data regarding a drug’s safety profile can be difficult to
obtain, because negative data are rarely published; moreover,
there is typically a delay in the availability of published
information for new drugs. Several sources can be explored,
however, depending on where the drug is in its life cycle.
Data can of course be found in the product labeling and from
meeting abstracts at the time of drug approval. If an advisory
committee hearing has taken place, then data may be found
at the FDA’s website [5]. This website is an underutilized
source of data for the formulary decision maker and even for
practicing clinicians who desire to know more about the
drugs they prescribe. Good examples exist of presentations
and accompanying discussions held at the FDA’s Advisory
Committee meetings, which are posted on the website in a
downloadable format (PDF files and PowerPoint slides).
Examples include the discussion of cardiac and renal
concerns related to the cyclo-oxygenase-2 inhibitors and
specific toxicities of voriconazole, telitromycin, moxifloxacin,
and newer generation antipsychotics. Although some of this
information has made its way into the published literature,
some of it remains unpublished and is only available on the
FDA’s website. In addition, if the drug has already been
approved in other countries, postmarketing studies may be
available in those countries.
Another factor has an impact on the availability of safety data.
Companies sometimes seek initial FDA approval for two
indications, particularly for antimicrobials. These indications
are usually skin and skin structure infections, acute
exacerbations of chronic bronchitis, acute bacterial sinusitis,
or urinary tract infections - indications for which it is easy to
enroll patients over a short period of time. Unfortunately, this
often leaves the clinician without data on other infections for
which the drug may be used. For example, tigecycline has
been on the market for a couple of years, but its initial
indications were for the treatment of complicated skin and
soft tissue infections and complicated intra-abdominal
infections. Pneumonia studies have only recently been
conducted. Although tigecycline may have been used off-
label for the treatment of hospital-acquired pneumonia or
ventilator-associated pneumonia (VAP), it failed to meet its
end-point of noninferiority compared with imipenem for
patients with VAP [6]. Therefore, we can find ourselves
feeling that we need to use a new antimicrobial for a
particular indication before clinical studies support such a
use. Having antibiotics available with enough data to support
a wide range of indications to assess properly their utility for a
yet wider range of indications does not necessarily go hand
in hand in the current regulatory climate. Gone are the days
when an antimicrobial came to the marketplace with 14
indications (for instance, trovafloxacin). The trend, especially
for antimicrobials, is to request FDA approval for one or two
indications and leave the clinician to determine whether the
drug may or may not work for other infectious diseases. As
we have learned (for example, from daptomycin and
tigecycline), it should not be assumed that an antimicrobial
approved for skin and skin structure infections will be
effective for other indications. Clinicians typically must wait
for 1 year for results from phase III trials to be published in a
respectable peer-reviewed journal. Interestingly, about half of
all drug withdrawals from the market occur within approxi-
mately 2 years of approval [7]. So, the first 2 years of the
antimicrobial’s time in the marketplace is very telling.
As mentioned above, antimicrobials lead all drug classes in
terms of numbers of adverse events [8]. Some adverse
events are class specific, but even within a class of anti-
microbials some agents may not be associated with the
adverse event at all. Examples include epileptogenic capa-
bilities among the various β-lactams. All β-lactams have some
potential to cause seizures, some more so than others.
Among the carbapenems, imipenem is most frequently
associated with seizures, whereas meropenem, ertapenem,
and doripenem are at the opposite end of the spectrum in
terms of risk for seizures. Similarly, macrolides/ketolides and
fluoroquinolones are associated with QT liability, but
azithromycin and ciprofloxacin stand out as not being
associated with the potential for causing QT prolongation.
For these reasons, new drugs should be viewed skeptically
when they are first approved for use and introduced for
formulary discussion.
For some antimicrobial classes, safety can be inferred from
previously introduced class members. For example, the β-
lactams have an established safety profile, with few if any
surprises when a new class member is introduced for clinical
use. Moxalactam is a well known exception to this long track
record of safety. Other than the moxalactam example, which
occurred several decades ago, the β-lactam family that
includes the penicillins, cephalosporins, cephamycins, mono-
bactams, and carbapenems has not had a class member
withdrawn from the marketplace because of an unexpected
and serious adverse event. For this reason, given adequate
safety data during a clinical development program, novel β-
lactams have been well accepted by hospital formularies
upon their release to the market so long as other
considerations, such as pricing and efficacy, are favorablePage 3 of 11
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relative to existing class members. On the flip side, the
opposite is true for the fluoroquinolones. In addition to the
known class effects, unusual and serious adverse events with
these agents have emerged shortly after their introduction to
the market. Examples include drugs that were actually with-
drawn from the market (for example, temafloxacin [hemolytic-
uremic syndrome] and trovafloxacin [hepatotoxicity resulting
in death or transplantation]). For this reason, formulary com-
mittees have been conservative in their adoption of new
fluoroquinolones until a proven track record has been
established.
Cardiac toxicity
Prolongation of the QT interval is an increasingly important
adverse event that has led to the withdrawal of certain drugs
from the market, many of them antimicrobials. Although
prolonged QT interval rarely has consequences (such as life-
threatening ventricular arrhythmias, specifically torsades de
pointes), they are severe [9-11]. The fluoroquinolones (except
for ciprofloxacin), macrolides/ketolides, and azoles have been
shown to prolong the QT interval [9,11-13].
QTc prolongation occurs as a result of a drug’s affinity
toward binding to a particular potassium channel in the
cardiac myocyte (delayed rectifier potassium channel; IKr).
The prevalence and risk associated with this prolongation
depends on drug-related and patient-related factors,
including the dose and route of administration, the drug’s
individual propensity for binding to IKr channels, the number
of channels present in an individual patient (reduced numbers
exist in patients with congestive heart failure and in women),
and genetic anomalies within these and other cardiac
channels. In addition, organ dysfunction or the concomitant
administration of other medications can increase this risk by
delaying metabolism of the QT interval prolonging drug or
enhancing drug exposure, or by causing electrolyte derange-
ments [9,10]. Furthermore, concurrently administered medi-
cations may have direct effects of their own on these
channels, augmenting the overall effect on the QT interval.
The affinity of various antibiotics for these channels varies
substantially. For example, 50% inhibition of the IKr channel is
produced by a 33 μmol/l concentration of clarithromycin, a
42.5 μmol/l concentration of telithromycin, a 72 μmol/l
concentration of erythromycin, a 129 to 353 μmol/l concen-
tration of moxifloxacin, and a 966 μmol/l concentration of
ciprofloxacin [10]. In contrast, less than a 1 μmol/l concen-
tration of sotalol or terfenadine is required to produce 50%
inhibition [11].
Overall duration of exposure also plays an important role [14].
Single doses of a drug are not likely to cause torsades de
pointes; however, the probability that this particular adverse
event will occur rises sharply when a full course of therapy is
administered. In general, the median time to torsades de
pointes is typically 4 to 5 days into therapy. β-Lactams,
including the carbapenems, have not been associated with
QT liability to date. In addition, preclinical screening tools are
now used to detect the potential for QT liability, so that it can
be assessed early in development (moxifloxacin) rather than
waiting for postmarketing studies to elucidate this finding
(droperidol).
Dysglycemias
Dysglycemias (hypoglycemia and hyperglycemia) are un-
common adverse events associated with some antimicrobials,
including certain fluoroquinolones, particularly gatifloxacin
[13,15]. Historically, quinine has been associated with
dysglycemias. The quinolones, which are structurally related
to quinine vis à vis quinoline rings, have a penchant to
influence the release of insulin (gatifloxacin, temafloxacin, and
clinafloxacin more so than others) [13,15]. Other anti-
microbial classes appear to be devoid of the potential to
disrupt glucose homeostasis. The purported pathophysiology
of perturbations in glucose homeostasis (specifically
hypoglycemia) is mechanistically similar to that observed with
QT interval prolongation. A potassium channel exists within
pancreatic β cells that is genetically similar to the one present
in cardiac myocytes. Fluoroquinolones (particularly gatifloxa-
cin, temafloxacin, and clinafloxacin) have a collateral affinity
toward this channel, resulting in partial blockade and leading
to an accumulation of intracellular glucose within these β
cells, and insulin is secreted in response to this artificially
elevated glucose concentration [16]. For example, clinafloxa-
cin exposure resulted in a substantial increase in insulin
release (from 165% to 235%) that triggered a reduction in
blood glucose by 47% to 51% [13,15]. This is an extreme
example within the fluoroquinolone class. Substantially
smaller disturbances in blood glucose have been determined
with other class members.
The reason why this is clinically unnoticed in patients is
explained by the fact that the body is remarkable in its ability
to compensate physiologically for small fluctuations in glucose
regulation [13,15]. However, symptomatic hypoglycemia can
develop in susceptible individuals who lack these compen-
satory mechanisms (for example, patients with underlying
diagnosed or undiagnosed diabetes and those receiving
corticosteroids) [15]. Gatifloxacin gained notoriety for
complications that were detected in postmarketing studies.
Clinafloxacin’s proclivity for this rare but serious adverse
event was determined during its clinical development program
and may be among the reasons why its submission to the
FDA was withdrawn by the company after completion of its
phase III studies [13,15].
Clostridium difficile infection
C. difficile infection (CDI) is an emerging, complex, and
important patient safety issue; it is an adverse event almost
exclusively associated with antibiotic administration. Acquisition
of CDI is a multifactorial process that involves antibiotic use,
exposure to the organism, and a variety of host factors,
Available online http://ccforum.com/content/12/S4/S3including age, immune status, and gastric acid suppression
[13,17]. Consequently, the risk for CDI can be substantially
reduced through good antimicrobial stewardship, compliance
with infection control practices, and appropriate
environmental intervention [17,18]. A number of reasons for
the increased incidence of CDI have been proposed and are
discussed in detail elsewhere [19]. In brief, the appearance of
a previously uncommon, toxin gene variant of C. difficile that
possesses additional resistance characteristics (to
fluoroquinolones) has emerged as a predominant cause of
CDI throughout North America and as far away as Japan [20].
Because of the virulence associated with this new strain of C.
difficile, careful attention to antimicrobial selection and
duration of therapy has become an important tool in
combating this infection.
The individual risk associated with each antimicrobial is
probably different. Studies to date have been unable to
distinguish antimicrobial risk at the ‘micro’ level but they were
able to elucidate differences at the ‘macro’ level. For example,
the cephalosporins, fluoroquinolones, and variably clinda-
mycin have topped the list of antimicrobials that have been
associated with the emerging toxin gene variant strain of C.
difficile known as BI/NAP1. This is due, in part, to the fact
that the aforementioned drug classes possess no or variable
activity against C. difficile. Antimicrobials with activity against
C. difficile (for example, metronidazole, piperacillin-tazobactam,
tetracyclines including tigecycline, and to some extent the
carbapenems) have been associated with CDI less often than
those classes of drugs to which in vitro resistance is routinely
observed in clinical isolates [21,22]. In a review of the
literature, the odds ratios for C. difficile-associated disease
ranged from 1.3 to 36.2, depending upon the antibiotic
employed (Figure 1) [23]. Given the limitations inherent in
meta-analyses of trials with vastly different protocols, these
odds ratios are not listed for comparative purposes; however,
they illustrate the fact that all antibiotics are associated with
an increased risk for CDI [24]. Although carbapenems were
not included in this analysis, recent data demonstrate that this
class of antibiotics, like almost all others, carries a risk for CDI
[25,26]. And, a review of the newer literature evaluating
antimicrobial risk for CDI suggests that identified odds ratios
fall within the previously identified range, including carba-
penems [20]. Finally, it is important to remember that
although the risk for CDI increases with increasing duration of
antibiotic therapy, only a single dose is needed to increase
this risk [20,25,27].
Metabolic liability
Drugs that rely on cytochrome P450 (CYP) enzymes for
metabolism or inhibit these enzymes possess what is termed
‘metabolic liability’. Of the various CYP isoenzymes, CYP
3A4 is the most important because it is responsible for the
biotransformation of nearly 60% of all oxidized drugs [11].
Inhibiting the metabolism of a drug that relies on CYP 3A4
magnifies any associated toxicities inherent to that drug,
because most are dose (exposure)-dependent (for example,
hepatotoxicity, QT interval prolongation, and rhabdomyolysis).
Because polypharmacy plagues patients with HIV disease
and the elderly, the risk for drug interactions is increased
significantly in these populations [28]. In addition, patients
may be at risk for certain toxicities when they receive drugs
that carry metabolic liability, even in the absence of a direct
drug-drug interaction. The reason for this is that some
Critical Care    Vol 12 Suppl 4 Owens
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Figure 1
Pooled odds ratios and 95% confidence intervals for Clostridium difficile infection by antibiotic type. Adapted with permission from Bignardi.
Reprinted with permission [23]. Copyright © 1998 The Hospital Infection Society.patients are characterized genetically as poor metabolizer
phenotypes (typically more common with CYP 2C9 and CYP
2C19, which have specific impacts on the azole antifungals).
Patients with these poor metabolizer phenotypes are at risk
for dramatically reduced drug clearance when they are given
drugs that are metabolized through these CYP isoforms [11].
In general, antimicrobials that carry metabolic liability include
macrolides, ketolides, imidazole/triazole antifungals, and (to a
lesser degree) trimethoprim-sulfamethoxazole and ciprofloxa-
cin. To date, β-lactams, most fluoroquinolones, clindamycin,
and aminoglycoside antimicrobials do not possess metabolic
liability, making them safe to use in patients receiving
concurrent CYP P450 inhibitors and substrates.
A recent example demonstrates the ongoing importance of
unrecognized metabolic liability. A large population of
outpatients in a Medicaid claims database were evaluated
[29]. Patients who were receiving an antimicrobial (erythro-
mycin) concurrently with CYP 3A4 inhibitors were compared
with patients receiving CYP 3A4 inhibitors and/or β-lactam
antibiotics. A fivefold increase in cardiac sudden death was
reported in patients taking erythromycin-CYP 3A4 combina-
tions compared with recipients of CYP 3A4 inhibitors and/or
amoxicillin.
Immune-mediated adverse events
Immune-related antimicrobial harms are a common
complication of many antibiotics, including β-lactams, fluoro-
quinolones, glycopeptides, and sulfa drugs [4,13,30,31].
Hypersensitivity reactions producing rash, pruritus, and/or
urticaria are the most frequent and occur in up to 8% of
patients who receive a penicillin and up to 3% of patients
who receive a cephalosporin [32,33]. In contrast, anaphylaxis
develops in only 0.004% to 0.015%, and fatality due to this
anaphylaxis occurs in only 0.001% to 0.003% of penicillin
treatment courses [4].
Cross-reactivity occurs within the various classes of antibiotics.
For example, patients who have had an allergic reaction to
penicillin have a fourfold to sixfold increased risk for a reaction
upon exposure to other β-lactams [4]. Thus, a history of an
allergic reaction to penicillin has traditionally been sufficient to
exclude further therapy with all members of the β-lactam class
[4]. However, recent evidence suggests that this broad-based
exclusion is too conservative and prevents patients from
receiving first-line therapy, and often results in the patient
receiving a marginally effective therapy. It is important to
remember that patients should receive the most effective
agent, not a second-line or third-line treatment (unless
absolutely necessary). In some cases (for example, in patients
with cystic fibrosis) there are no second-line therapies for
certain pathogens; in these situations desensitization protocols
are used to facilitate the use of a first-line antimicrobial [34].
Between 5% and 20% of patients claim to have a history of
an allergic reaction to penicillin [3,4]. However, much of this
historical information is in error; only 10% to 20% of patients
reporting a penicillin allergy are truly allergic based on skin
testing [35]. Most of these ‘alleged’ allergic reactions to
penicillin represent predictable side effects of the drug or are
due to the infectious agent itself rather than the drug and do
not represent true type 1 hypersensitivity reactions [3,36].
Penicillin skin testing has a negative predictive value in
excess of 99% and is a safe and effective means of
determining which of these reactions represent a true IgE-
mediated response. In more than 2,000 patients who stated
that they were allergic to penicillin but had a negative skin
test, no life-threatening immediate reactions occurred during
penicillin therapy [36]. In 2002, Robinson and coworkers [3]
reported a useful algorithm to guide antibiotic selection in
patients with a history of penicillin allergy (Figure 2). When
using this algorithm it must be remembered that skin testing
is predictive only of IgE-mediated events; a negative skin test
does not decrease the probability of non-IgE-mediated events
[3]. However, these non-IgE-mediated events are frequently
related to side chains on the β-lactam ring [3], and so
affected patients may be less susceptible to cross-reactivity
with other members of the class or other classes of β-
lactams.
Cross-reactivity between penicillins and carbapenems would
be expected on the basis of structural similarity. However,
Available online http://ccforum.com/content/12/S4/S3
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Figure 2
Approach to antibiotic selection in patients with a history of penicillin
allergy. aIt is often difficult to obtain an accurate history; if in doubt,
assume that reaction could have been an urticarial rash. bAvoid use of
first-generation cephalosporins. Stevens-Johnson syndrome and toxic
epidermal necrolysis are not IgE mediated. If the suspected drug
reaction was either of these, then avoid skin testing and use of
penicillins. cSkin testing with amoxicillin is sometimes used if the
reaction was to amoxicillin, but the incidence of false negatives is
unknown. dIf the reaction was serious, then one may challenge in a
supervised setting using a ‘graded challenge’ with escalating oral
doses followed by intravenous administration, if applicable. Reprinted
with permission [3]. Copyright © 2002 the Infectious Diseases Society
of America.data evaluating the frequency of hypersensitive reactions in
penicillin allergic patients who receive a carbapenem are limited
to skin testing and retrospective evaluations [35]. In three
separate chart reviews, the prevalence rates of carbapenem
hypersensitivity in patients with a history of penicillin allergy were
9.5% [37], 11% [38], and 9.2% [39]. However, in only one of
these evaluations [38] was this risk significantly increased
relative to patients without a history of penicillin allergy. Because
precise and complete documentation is essential to differentiate
between allergic and nonallergic reactions and to establish the
temporal relationship of these reactions to therapy, the
retrospective nature of these evaluations substantially influences
the accuracy of these risk assessments.
Pending more definitive data, patients with a self-reported
history of a penicillin allergy that is not IgE mediated are
assumed to be at moderate risk for an associated adverse
event. These patients may receive a cephalosporin or
carbapenem if other treatment options are lacking and a
cephalosporin or carbapenem is deemed the most
appropriate option. Skin testing can be considered in patients
with suspected IgE-mediated penicillin allergy. In general,
patients with a positive skin test or other documented type 1
hypersensitivity to penicillin should avoid carbapenems
unless justified by the clinical circumstances. In the setting of
administering a cephalosporin or carbapenem to a patient
with a documented anaphylactic reaction to penicillin, the
patient should be desensitized using a published protocol in
the intensive care unit setting [3,35].
For example, my colleagues and I reported the successful
treatment of an acute pulmonary exacerbation due to multi-
drug-resistant Burkholderia cepacia and methicillin-resistant
Staphylococcus aureus (MRSA) in a patient with cystic
fibrosis [34]. We documented hypersensitivity by skin testing
to multiple antibiotics, including carbapenems, and a clinical
history of hypersensitivity after receiving imipenem. We
utilized a regimen of meropenem, tobramycin, and vanco-
mycin after meropenem desensitization using a 12-dose
escalation protocol. A number of our patients with cystic
fibrosis and histories of serious and life-threatening carba-
penem or penicillin hypersensitivities have been desensitized
to carbapenems. Desensitization has worked in these
patients with little trouble. In some cases the patient reacted
upon receiving the third or fourth escalating desensitization
dose; we returned to the previous concentration of drug to
which the patient did not react and infused that dose over a
longer time period (for example, from >20 to >40 minutes)
and then continued with 40-minute consecutive infusions
rather than the standard 20-minute infusions. It is important
that the patient does not miss any of the doses and that the
dose is administered on time (and not late). We often supply
extra doses on the nursing unit in case something happens to
one of the doses. Another important caveat is that patients
with Stevens-Johnson syndrome or exfoliative reactions
should not be challenged via desensitization.
Hepatotoxicity has been associated with amoxicillin/clavu-
lanate, oxacillin, and trovafloxacin [40-43]. In a series of
patients being treated as outpatients with intravenous
therapy, oxacillin was associated with a significantly increased
prevalence of hepatotoxicity (22%) as compared with nafcillin
(0%), clindamycin (1.4%), or other antimicrobials (1.4%; all
P < 0.001 versus oxacillin) [41]. Trovafloxacin was removed
from the market secondary to several deaths related to
hepatotoxicity [13,44].
Bone marrow suppression resulting in thrombocytopenia,
anemia, and/or neutropenia can develop when IgG or IgM
antibodies bind to antimicrobial antigens on the surface of
circulating cells, leading to lysis or opsonization of these cells
[4].  β-Lactams, including imipenem, linezolid, and glyco-
peptides, have all been associated with various forms of bone
marrow suppression [30,41,45,46].
Central nervous system adverse events
β-Lactams, fluoroquinolones, and isoniazid are associated
with increased risk for seizures [13,47,48]. In fact, β-lactams
are frequently used to induce seizures in animal models [49].
At high enough doses, all β-lactams can induce seizures.
However, because the problem is recognized and because of
use of appropriate dosing regimens, seizures as a complica-
tion of β-lactam use had almost fallen into obscurity before
the launch of imipenem [50]. Because high-dose (4 g/day)
imipenem was thought to be more effective than a 2 g/day
dosing regimen in certain infections, and because early
clinical trails suggested that 4 g/day was safe [51,52], the
higher dosing regimen was evaluated. As a result, imipenem
was approved by the FDA for use at a dose of up to 4 g/day
(1 g every 6 hours). However, subsequent analysis of phase
III dose-ranging studies showed that imipenem was asso-
ciated with a dose-dependent risk for seizures, with a risk of
3.6% associated with daily doses exceeding 2 g/day [47]. In
addition, a trial for the treatment of bacterial meningitis had to
be halted prematurely when 33% of the patients receiving
imipenem developed seizures [53]. This risk for seizure has
led to extensive revision of the recommended dosing regimen
for imipenem. The new scheme, which involves type and
severity of infection, susceptibility of the organism, six cate-
gories of patient size, and five categories of renal function, is
among the most complicated for any pharmaceutical agent
approved for use in the USA [54]. This complicated dosing
regimen, coupled with a fear of inducing seizures, has
resulted in the underdosing of imipenem in clinical settings,
‘just to be safe’. Suboptimal dosing of imipenem may reduce
its efficacy for difficult infections and contribute to the rapid
emergence of resistance in Pseudomonas aeruginosa, which
is of particular concern for carbapenems (see below).
Although FDA-approved labeling warns of a seizure risk with
all carbapenems, this risk appears to be most significant with
imipenem. The seizure rate in pivotal trials of newer
carbapenems is reported to be 0.7% or less [55,56]. The
Critical Care    Vol 12 Suppl 4 Owens
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their ability to bind to and competitively inhibit the γ-amino-
butyric acid receptor in the brain [57], and the affinity of
imipenem for this receptor is substantially greater than that of
meropenem. In an animal model, the concentration of
meropenem required to achieve 50% inhibition of γ-amino-
butyric acid receptors in cerebral cortical membranes was
more than 20-fold greater than that required with imipenem
(Figure 3) [57]. Consistent with this, intracerebroventricular
injection of 100 μg of imipenem into dogs induced facial
spasms, twitching, falling back, and clonic convulsions,
whereas a similar dose of meropenem had no effect on
behavior [57]. Ertapenem and doripenem appear to behave
similarly to meropenem rather than to imipenem. The central
nervous system safety of meropenem can be highlighted by
the fact that it is approved for the treatment of meningitis,
whereas for imipenem one-third of all patients with meningitis
suffered from seizures.
Other, and sometimes subclinical, neurologic effects can be
elicited by beta-lactams. This has been noted for nearly if not
all members of this class. Of late, a paper or two has
highlighted these effects with the use of  the now generic
cefepime. While true, cefepime can cause subclinical and
clinical neurologic effects which may manifest as delirium,
psychosis, aphasia, somnolence, and insomnia, a myriad of
other causes for these effects can be culprits. In one case
report and review of the literature, cefepime was concluded
to be similar to ceftazidime with respect to neurologic
adverse events [58]. One common theme tying together
these case reports were the fact that nearly all of the patients
unequivocally had kidney disease or were on some form of
hemodialysis or filtration modality, yet were given unadjusted
doses of cefepime. In modern times, we would call these
“medical errors”. Unlike most institutions where renal dosing
takes place, one paper reported extreme overdoses, so much
so it is not any wonder why the patients did not demonstrate
frank seizures resulting in litigious action [59]. One of these
patients with end stage kidney disease received, on average,
almost 9 grams per day for five days [59]! The only
cephalosporin, monobactam, or carbapenem that does not
require attention to renal dosing is ceftriaxone. For all other
aforementioned antimicrobial classes, the clinician needs to
be cognizant of renal dosage adjustment in the context of the
infection being treated [60]. Otherwise, one can be
castigated, at minimum, for such a great responsibility which
cannot be ignored, as happened in the paper in question. It
also should be remembered that the fluoroquinolones exhibit
neurologic adverse events as well, manifesting similarly to
beta-lactams [61]. A heightened awareness of this issue is
warranted for these classes of drugs.
Emergence of resistance
Although not typically thought of as an adverse event,
emergence of resistance is a major adverse sequela of
antibiotic use [62]. In a retrospective review of 173 studies
involving more than 14,000 patients and 225 individual treat-
ment regimens, emergence of resistance occurred in 4% of
all organisms and complicated 5.6% of all infections treated
[63]. Emergence of resistance was greatest for P. aeruginosa
infections and appeared to be associated with β-lactams,
aminoglycosides, and fluoroquinolones [63]. Currently,
carbapenems retain a broad spectrum of activity that includes
most  β-lactamase producing organisms [64]. However,
preserving this activity will require good antimicrobial
stewardship that involves using them appropriately, at the
correct dose, and for the correct duration [24]. For example,
studies have demonstrated that VAP can be treated for as
few as 7 to 8 days of therapy, as long as the patient initially
received effective antimicrobials (specifically, the pathogen
eventually isolated turns out to be susceptible to the initially
selected empirical treatment choice) [65]. It is important to
note that patients with life-threatening infections, such as
health care associated pneumonia or sepsis, must receive
initially appropriate therapy, because observations in clinical
practice have demonstrated that this does not routinely occur
in some centers. One can take the recommended approach
that reflects a Chinese menu, whereby one selects a drug
from column A (carbapenem, piperacillin-tazobactam, or
cefepime) and one from column B (an aminoglycoside or an
antipseudomonal fluoroquinolone) plus or minus one from
column C (an anti-MRSA treatment option). The individual
choices should be dictated by the hospital’s anibiogram.
These broad-spectrum regimens will ensure that the patient
receives adequate therapy initially.
Although some are fearful of this broad-spectrum approach,
the key is to de-escalate therapy on day 3, when the results of
the culture return, and to stop therapy in 7 to 8 days as long
as the patient has clinically responded to the regimen.
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Figure 3
Concentrations of various penems and their displacement of GABA
from their receptor sites. Illustrated is the concentration-dependent
displacement of muscimol by meropenem, panipenem, and imipenem
at the γ-aminobutyric acid (GABA) receptor in mouse cerebral cortical
membranes [66].Therapy for P. aeruginosa or  Acinetobacter  spp. may be
extended for up to 10 days, but the longer the patient receives
antimicrobials, the more likely the patient is to develop
resistance to the antimicrobials being administered. Unfor-
tunately, clinical guidelines that some clinicians consider a
‘bible’ for antimicrobial information contain ‘random’ and non-
evidence-based statements. For example, for pneumonias
caused by P. aeruginosa or other Enterobacteriaceae, the
Sanford Guide 2007 [66] recommends ‘21 days, often up to
42 days’ as the duration of therapy. Discrepancies between
quick pocket guides and randomized controlled trials
sometimes contribute to confusion in the trenches.
Numerous evaluations have demonstrated that imipenem can
select for emergence of resistant Gram-negative organisms
such as P. aeruginosa (Figure 4) [67-72]. In an early meta-
analysis [67], 18% of P. aeruginosa isolates developed resis-
tance to imipenem during therapy for a variety of infections.
Furthermore, the incidence was 32.8% (41/125) in
respiratory tract infections. In a cohort evaluation, the hazard
ratio for the emergence of resistant P. aeruginosa was
greater for imipenem therapy (44; P = 0.001) than for pipera-
cillin (5.2; P = 0.01), ciprofloxacin (9.2; P = 0.04), or ceftazi-
dime (0.8; P = 0.7) therapy [68]. In a subsequent, open-label
prospective evaluation [69], this hazard ratio was greater for
imipenem therapy (7.8; 95% confidence interval 3.4 to 18.1)
than for piperacillin-tazobactam (3.9; 95% confidence interval
1.3 to 11.9) or cefotaxime (9.3; 95% confidence interval 2.9
to 30.2) therapy.
A single mutation in P. aeruginosa confers resistance to
imipenem; in contrast, resistance to newer carbapenems,
such as meropenem, requires two separate and distinct
mutations [62,73]. As a result, emergence of resistant P.
aeruginosa appears to be less likely with the newer
carbapenems than with imipenem [74]. The clinical
significance of this may vary from center to center, and the
percentage susceptibility of each carbapenem to various
problematic pathogens should dictate which one is selected
for an individual formulary.
Prolonged infusion as a means to optimize
patient safety and enhance potential efficacy
Carbapenems are characterized pharmacodynamically as time-
dependent killers. In other words, bacterial killing is optimized
when the duration of time that the antibiotic concentration
exceeds the minimum inhibitory concentration (MIC) of the
infecting pathogen for a given period of the dosing interval
[24]. The time above MIC requirements for optimal efficacy of
carbapenems varies by pathogen and happens to be the least
amount of time required compared with other β-lactam
antimicrobials [75]. Certain adverse events are dose-
dependent or concentration-dependent, including seizures,
nausea, and vomiting. Consequently, extending the duration of
the carbapenem infusion can maximize time above MIC and
can be a particularly useful tool when dealing with pathogens
such as P. aeruginosa, which have higher MIC values but
remain within the susceptible or potentially intermediate
resistant breakpoint range. In some cases, in which high MIC
values are noted for the infecting organism, both increasing the
dose and prolonging the infusion interval can result in an
optimized time above MIC and improve the probability of a
clinical response. Selecting a drug within the class that
possesses the lowest MIC value for a particular pathogen also
helps in resolving the pharmacodynamic equation, in simple
terms, because lower MIC values require less drug to maintain
an adequate time above MIC. This is commonly done in clinical
practice, but for concentration-dependent killing agents such
as the aminoglycosides. Tobramycin typically possesses
twofold to fourfold lower MIC values than gentamicin for strains
of  P. aeruginosa. In this case, the magnitude of the ratio
between the peak concentration and the MIC value is an
important determinant of bacterial killing. Given that tobramycin
and gentamicin have identical pharmacokinetic properties and
achievable peak concentrations, simply choosing the
aminoglycoside with the lowest MIC can double or quadruple
the ratio of peak concentration to MIC.
Monte Carlo simulations have been performed for various
carbapenem-pathogen combinations and dosing regimens.
Meropenem 500 mg infused over a 3-hour period every
8 hours yielded a time above MIC comparable to 1 g
meropenem infused over 1 hour every 8 hours or 500 mg imi-
penem infused over 1 hour every 6 hours [76]. In addition, the
blunted peak concentrations observed with prolonged infusion
times have been shown to be beneficial in terms of reducing
the gastrointestinal adverse effects associated with imipenem
therapy [72,77]. Prolonged or extended infusion of β-lactam
therapy is preferred to continuous infusion, because intra-
venous therapy can be administered more frequently and the
intravenous catheter is not tied up for the entire 24-hour day.
The ability to extend infusion durations in the clinic can be
impeded by the duration of stability once the solution is
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Figure 4
Cumulative risk for emergence of Gram-negative resistant organisms
by treatment and duration of hospitalization. Adapted with permission
[70]. Copyright © 2001 the Infectious Diseases Society of America.prepared. In this regard, imipenem is slightly less stable than
meropenem, limiting its practical utility in clinical practice. In a
comparative evaluation of the stability of both carbapenems in
aqueous solution at room temperature, 10% degradation
occurred after only 3.5 hours with imipenem, as compared
with 5.15 hours with meropenem [78]. Future carbapenems
would optimally have even longer stability in aqueous
solution, improving the ability to extend infusion durations and
increasing the number of indications for which extended
infusions are approved. But these pharmacodynamic
concepts are not new at all. Harry Eagle [79] demonstrated
that continuous versus discontinuous administration of
penicillin was an efficient and effective method of optimizing
beta-lactam therapy in the late 1940s. Perhaps some 60 plus
years later, we can take advantage of his observations at the
bedside.
Conclusion
One of the chief concerns in prescribing antimicrobial therapy
or selecting agents for hospital formularies is a drug’s
potential to cause harm. The harm can be a class effect or
uniquely associated with a particular class member. No
unexpected harms have been reported for FDA approved β-
lactams for decades, since moxalactam caused serious
complications associated with bleeding events. This is not to
say we should be complacent about sensitivity to the potential
for harms within this class. In contrast, drug classes such as
the fluoroquinolones have been subjected to a great deal of
scrutiny, given the checkered history of unexpected toxicities
and withdrawals from the market. New methods for optimizing
the pharmacodynamics of β-lactams with short half-lives (for
example, prolonged infusions) have the potential not only to
increase the time above MIC for pathogens with higher MIC
values, potentially leading to enhanced efficacy, but also to
blunt peak concentration-related toxicities. Because of their
activity against a broad spectrum of resistant pathogens such
as  P. aeruginosa and extended-spectrum β-lactamase
producing Enterobacteriaceae, the carbapenems are
increasingly being incorporated into first-line therapy protocols
and pathways for the treatment of serious health care
associated infections. Ultimately, as with other drug classes,
the carbapenems must be used judiciously. Antimicrobial
stewardship programs can ensure that this class of
antimicrobials, along with others, is used at the appropriate
doses and, importantly, for the shortest possible time.
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